share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KASINGER JAMES R.

SEC announcement ·  Mar 23 05:48
Summary by Futu AI
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, has been reported to engage in a transaction involving the company's stock. The action took place on March 20, 2024. However, the announcement did not disclose the type of action, the status, the number of shares involved, the nature of the shares, the transaction price, or the post-transaction shareholding details. Without these specifics, the impact of this event on CRISPR Therapeutics' stock remains unclear to investors.
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, has been reported to engage in a transaction involving the company's stock. The action took place on March 20, 2024. However, the announcement did not disclose the type of action, the status, the number of shares involved, the nature of the shares, the transaction price, or the post-transaction shareholding details. Without these specifics, the impact of this event on CRISPR Therapeutics' stock remains unclear to investors.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.